Bone Fracture - Pipeline Review, H1 2015

05:00 EDT 8 Jun 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Bone Fracture - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-04-28. This 80-page report is available in PDF from $2000.

Bone Fracture - Pipeline Review, H1 2015


Global Markets Direct’s, ‘Bone Fracture - Pipeline Review, H1 2015’, provides an overview of the Bone Fracture’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Bone Fracture, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Fracture and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- The report provides a snapshot of the global therapeutic landscape of Bone Fracture
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Bone Fracture and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Bone Fracture products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Bone Fracture pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of…

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Bone Fracture Overview 9
Therapeutics Development 10
Pipeline Products for Bone Fracture - Overview 10
Pipeline Products for Bone Fracture - Comparative Analysis 11
Bone Fracture - Therapeutics under Development by Companies 12
Bone Fracture - Therapeutics under Investigation by Universities/Institutes 14
Bone Fracture - Pipeline Products Glance 15
Clinical Stage Products 15
Early Stage Products 16
Bone Fracture - Products under Development by Companies 17
Bone Fracture - Products under Investigation by Universities/Institutes 18
Bone Fracture - Companies Involved in Therapeutics Development 19
Arcarios BV 19
AstraZeneca PLC 20
Biogenomics Limited 21
Bone Therapeutics SA 22
Escape Therapeutics, Inc. 23
Juventas Therapeutics, Inc. 24
Kaken Pharmaceutical Co., Ltd. 25
Kolon Life Science, Inc. 26
Kuros Biosurgery AG 27
Laboratorios SALVAT S.A. 28
Novartis AG 29
OrgaNext Research BV 30
TissueGene, Inc. 31
Viking Therapeutics, Inc. 32
Bone Fracture - Therapeutics Assessment 33
Assessment by Monotherapy Products 33
Assessment by Combination Products 34
Assessment by Target 35
Assessment by Mechanism of Action 37
Assessment by Route of Administration 39
Assessment by Molecule Type 41
Drug Profiles 43
(nandrolone decanoate + cholecalciferol) - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
ALLOB - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
AZD-2858 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
bimagrumab - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
denosumab biosimilar - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
dibotermin alfa - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Drugs to Modulate Bone Morphogenetic Protein for Osteoarthritis and Fracture - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Drugs to Modulate PPAR-Delta for Immunology, Metabolic and Musculoskeletal Disorders - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Gene Therapy for Bone Fracture - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
JVS-200 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
KCB-1B - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
KLS-Bfr - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
KUR-111 - Drug Profile 56 For more information open Bone Fracture - Pipeline Review, H1 2015.


Original Article: Bone Fracture - Pipeline Review, H1 2015


More From BioPortfolio on "Bone Fracture - Pipeline Review, H1 2015"

Quick Search


Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Osteoporosis is a disease in which the bones become extremely porous, are subject to fracture, and heal slowly, occurring especially in women following menopause and often leading to curvature of the spine from vertebral collapse. Follow and track&n...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...